Antisense Therapeutics’ Phase II Trials Show Promise for New Muscular Dystrophy Drug
Duchenne’s Muscular Dystrophy (DMD) is a devastating generic muscular wasting disorder with a 100% fatality rate . At
News
Antisense
- About
- News and media
- Upcoming Events
- Recent Events
- Investment Webcasts
- Trading Webcasts
- The Insider
- Meet the CEOs
- Meet the Fund Manager
- Technical Investing
- Armytage Private Limited
- Eley Griffiths Group
- Pengana Capital Group
- Eiger Capital
- Capital H Management
- NAOS Asset Management
- K2 Asset Management
- Viriathus Australia
- Cyan Investment Management
- Gleneagle Securities
- Yarra Capital Management
- OC Funds Management
- Arnott Capital
- Lucerne Investment Partners
- TAMIM Asset Management
- Thorney Investment Group
- ASX Company Webcasts
- INVESTMENTS
- Trading
- Reach Corporate
- CONTACT